MEDISEARCHER NEWS United Kingdom · Weight-loss medicines · 16 October 2026 In brief UK authorities have seized more than 12,000 fake retatrutide and tirzepatide injection pens during a raid on an industrial unit in Birmingham. The Medicines and Healthcare products Regulatory Agency (MHRA) estimates the seized products were worth approximately £2 million. Investigators also found … Read more
MEDISEARCHER NEWS European Union · Pancreatic cancer · 16 October 2026 In brief The European Medicines Agency’s medicines committee has recommended Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic treatment. In the pivotal Phase 3 trial, median overall survival was 12.4 months with daraxonrasib compared with 6.7 … Read more
The most common side effects of Ozempic are gastrointestinal, particularly nausea, diarrhoea, vomiting, abdominal pain and constipation. These effects are often most noticeable when treatment begins or the dose is increased and may improve as the body adjusts to semaglutide. Ozempic can also cause less common but potentially serious problems. These include pancreatitis, gallbladder disease, … Read more
Tirzepatide is usually started at 2.5 mg once weekly and increased gradually in 2.5 mg steps. However, there is no single tirzepatide dose that is right for everyone. The appropriate maintenance dose depends on the product, treatment indication, response and tolerability. In the United States, tirzepatide is sold as Mounjaro and Zepbound. Although both contain … Read more
MEDISEARCHER NEWS Global · Pulmonary fibrosis · 14 October 2026 In brief Admilparant, an experimental oral treatment for idiopathic pulmonary fibrosis (IPF), has met the primary endpoint in a pivotal Phase 3 clinical trial. The 60 mg twice-daily dose produced a statistically significant benefit in lung function at 52 weeks compared with placebo. The higher … Read more
MEDISEARCHER NEWS Ireland · GLP-1 access · Updated 15 October 2026 In brief Ireland’s HSE Drugs Group considered Mounjaro (tirzepatide) at its meeting on 13 October but did not make a reimbursement recommendation. Mounjaro remains available by prescription in Ireland but is not currently covered by the Medical Card, Long-Term Illness Scheme or Drugs Payment … Read more
MEDISEARCHER NEWS Sweden · GLP-1 access · 11 October 2026 In brief Wegovy tablets are now available from Swedish pharmacies, including through pharmacy websites, before manufacturer Novo Nordisk has officially launched the oral version in Sweden. The initial supply has reached Sweden through parallel import or distribution from another EU market rather than Novo’s own … Read more
MEDISEARCHER NEWS United States · Medication Regulation · 9 October 2026 In brief: The Trump administration is reportedly considering an interim policy that could expand access to BPC-157, TB-500 and several other peptides through compounding pharmacies. The FDA has not approved these peptides, and as of 9 October 2026 MediSearcher has not identified a new … Read more
MEDISEARCHER NEWS United Kingdom · Weight-Loss Medicines · 7 October 2026 In brief: UK regulators have stepped up enforcement against online advertising for prescription weight-loss medicines, with five new Advertising Standards Authority (ASA) rulings involving online pharmacies and weight-loss services. The action comes just five days after the Medicines and Healthcare products Regulatory Agency (MHRA) … Read more
MEDISEARCHER NEWS Australia · Medication Access · 6 October 2026 In brief: Eli Lilly has launched LillyDirect in Australia, allowing people with an electronic prescription for eligible Lilly medicines to arrange pharmacy dispensing and home delivery through an online platform. The initial service includes Mounjaro (tirzepatide). Lilly says the service offers competitive pricing and included … Read more
